US 7,731,950 B2 · Attack of tumor cells with missing, low or aberrant MHC expression by combining non MHC-restricted T-cells/NK-cells and MHC-restricted cells

Abstract

This invention is directed to therapeutic compositions containing non-MHC-restricted T-cells/NK-cells in combination with MHC-restricted T-cells and especially to therapeutic compositions, which comprise LAK cells. Furthermore, the present invention is directed to the use of the above combination in the treatment of tumors in humans, which tumors show a missing, low or aberrant expression of MHC class 1a or 1b molecules. By using the aforementioned compositions/combinations it is possible to provide a balanced selective pressure against emergence of tumor cell variants that would otherwise escape immune detection.

Claims3

Dependent claims

A therapeutic composition comprising:

a) a preparation of activated non-MHC-restricted T cells comprising Lymphokine Activated Killer T cells (LAK T cells), wherein the LAK T cells are prepared by culturing a preparation of peripheral blood mononuclear cells (PBMCs) in a culture medium comprising at least about 1000 units/ml of human interleukin 2 (IL-2) for at least two weeks;
and
b) a therapeutic agent for inducing immune responses of MHC-restricted T cells selected from the group consisting of a genetically engineered tumor cell and a vaccine comprising tumor cells or dendritic cells.

Dependencies are inferred from the claim text.

Facts

Application

10/190,281Filed 5 Jul 2002

Priority

DE 101 32 5025 Jul 2001

Published

US 2003/0095955 A122 May 2003

Granted

8 Jun 2010

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/15
Characterised by the cell type used: natural-killer [NK] cells; Natural-killer T [NKT] cells
A61K 40/42
Vertebrate antigens: cancer antigens

Attack of tumor cells with missing, low or aberrant MHC expression by combining non MHC-restricted T-cells/NK-cells and MHC-restricted cells

Life of this patent

Attack of tumor cells with missing, low or aberrant MHC expression by combining non MHC-restricted T-cells/NK-cells and MHC-restricted cells

Life of this patent

Abstract

Claims3